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A B S T R A C T
Purpose: Neuropsychology has become an essential diagnostic tool for epilepsy-related cognitive
comorbidities and treatment evaluation. However, a lack of resources may prevent routine
neuropsychological assessments outside specialized epilepsy centers. Computerized testing appears
to offer a time- and cost-effective approach to assess cognitive functions in patients with epilepsy.
Moreover, the technical advances of computerized tests provide interesting tools to address speciﬁc
diagnostic questions around epilepsy. This review is intended: (1) to outline the advantages and
disadvantages of computerized testing, (2) to delineate its indications and ﬁelds of application, and (3) to
give an overview of available tools that have been applied in epilepsy or antiepileptic drug research.
Method: Iterative review of computer-based neuropsychological assessment batteries previously
applied in clinical epileptological settings or antiepileptic drug trials.
Results: Among nine reviewed computer tests merely three were explicitly devised for epilepsy and
showed sensitivity to clinical parameters like focus lateralization or localization or the presence/absence
of epileptiform activity. Concurrent validity with established measures was demonstrated for two of
these three tests. Some sensitivity to antiepileptic pharmacotherapy was reported for seven of all nine
reviewed test batteries.
Conclusion: Additional studies are needed to demonstrate the sensitivity and speciﬁcity of computerized
neuropsychological tests to epilepsy and treatment related variables. In most clinical scenarios exclusive
computerized testing cannot substitute a thorough neuropsychological examination in patients with
epilepsy at present.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Neuropsychology provides evidence-based methods to answer
clinical questions regarding epilepsy and its treatment.1 Apart
from its role in the assessment of cognitive dysfunction in relation
to the type of epilepsy and the underlying pathology, neuropsy-
chology plays an increasing role in the individual quality and
outcome control of all kinds of medical interventions, be they
invasive (e.g. epilepsy surgery, radio- or stereotactic surgery, deep
brain stimulation), semi-invasive (e.g. vagal nerve stimulation) or
non-invasive (pharmacological treatment).2,3
As a consequence of the increasing dissemination and accep-
tance of neuropsychological diagnostics for monitoring CNS
(central nervous system) diseases and treatment outcomes, thereDOI of original article: http://dx.doi.org/10.1016/j.seizure.2012.08.011
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http://dx.doi.org/10.1016/j.seizure.2013.04.004is the understandable interest in brief, cost effective, and easy-to-
apply assessment and screening tools. Technical advances during
the last decade now offer a unique possibility to transfer
neuropsychological assessment into the world of computers,
laptops, tablets, handheld devices and mobile phones. The transfer
to and the utilization of such novel testing platforms is only just
beginning. Nevertheless there has been an increasing interest in
computerized diagnostics in patients with epilepsy.
The quality of neuropsychological results – and this holds true
in equal measure for computerized as well as classical paper-pencil
tests – depends on the validity of the neuropsychological
instruments applied. The chosen measures and testing methods
need to be sensitive and speciﬁc in regard to the intended ﬁeld of
application and the underlying clinical question. Beyond the three
classical test criteria of ‘‘objectivity’’, ‘‘reliability’’ and ‘‘validity’’,
the following additional criteria have to be considered: the quality
and range of the normative data provided, the availability of
parallel test versions and information about practice effects due to
repeated test administration, i.e. test-retest norms. Furthermore,
the effort in terms of time (duration of administration and scoring)
and costs (test materials and staff) are relevant. Finally, the bestvier Ltd. All rights reserved.
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not valid in a particular patient group because of cultural
variations.4
2. The pros and cons of computerized assessments
Computerized neuropsychological tests usually have a high
objectivity in terms of administration and scoring. A high level of
test objectivity is a required but not sufﬁcient precondition for
high test-reliability. The same is true for the relation between
test reliability and test validity. In contrast to paper-pencil
testing, computer tests allow for the exact assessment of reaction
times in milliseconds. This is particularly advantageous when
evaluating processes of attention (e.g. alertness/speed of
information processing). Furthermore, computerized tests can
make use of enhanced interactive and multimedia-based
question styles or virtual realities. They do not require stationary
hardware since they can potentially be used on mobile phones or
handheld computers. The possibility of a continuous and instant
registration of cognitive performance can be utilized for adaptive
testing, i.e. the tailoring of the task difﬁculty/demands to the
individual performance level. The possibility of randomly
selecting items from a pool of stimuli instead of using ﬁxed
parallel versions is an advantage when multiple reassessments
are required. Moreover, computer tests are usually easy to
administer or even self-administrable. Although the application
thus does not necessarily require neuropsychological expertise,
computerized testing without neuropsychological supervision
bears the risk of false interpretations. Fully computerized tests
must be differentiated from computer-guided or -aided tests.
Whereas ‘‘fully computerized’’ implies computerized task
presentation and automated response registration, computer-
guided or -aided testing uses the computer either for stimuli
presentation or as an electronic log sheet where the examiner
records the patient’s reactions/answers. Therefore computer-
guided or -aided testing is by deﬁnition not self-administrable
and always requires an examiner.
If the registration of results is computerized, computer tests can
provide a fully automated calculation and presentation of the
ﬁndings (in terms of raw data as well as standardized values
related to normative data), which can be included in printed
reports or electronic patient ﬁles automatically. This is time-
efﬁcient and also allows clinicians to provide instantaneous
feedback to the patient investigated. In the context of scientiﬁc
studies, the possibility of an electronic data export facilitates the
import into statistical software packages. A major advantage of
computerized testing, especially for the ﬁeld of epilepsy, is the
possibility of time-locked coregistration of cognitive processes and
physiological measures. By this means the impact of interictal
epileptiform discharges on cognitive performance can, for exam-
ple, be analyzed. Apart from concomitant EEG-analyses, comput-
erized tests can also be applied during functional brain imaging
studies (e.g. fMRI). Finally, although the up-front equipment cost of
computerized testing procedures may be higher, there may be
savings in the long run since paper-pencil tests require constant
restocking of log sheets.
Computerized neuropsychological tests may also have some
disadvantages. Self-administrable computerized tests dramatical-
ly reduce the interaction between examiner and patient. Therefore
a potentially important source of information is lost. Another
disadvantage can be seen in interface problems, e.g. behavioral
responses are reduced to reactions via mouse, keyboard or joystick.
For example, the exact position of the index ﬁnger (e.g. the distance
between ﬁnger and key) may be important for the measurements
of reaction times in milliseconds. The increasing availability of
more intuitive touchscreens may attenuate such reservations.Future and advanced techniques of video-monitoring, language
recognition or movement registration may expand the variety of
behavioral expressions. Principally, individual differences in
regard to the familiarity with computer devices may affect the
afﬁnity to and the performance in computerized tests.
Another issue is that some well-validated traditional paper-
pencil tests require written or spoken responses (e.g. free verbal
memory recall), patient drawings or manual constructions (e.g.
using blocks). This cannot be easily converted into a computerized
test – at least not without extensive validation of new patient-test
interaction methods. Finally, some computer test batteries require
extra hardware (e.g. push-button, touchscreen) or have special
software requirements (e.g. in terms of the operating system used).
Differences in screen sizes and contrast/clarity may affect results
and it can be difﬁcult to adjust the audio volume when presenting
sounds or speech.
3. Indications for computerized tests
For which diagnostic questions in the ﬁeld of epilepsy are
computer tests suitable? The use of a computerized test battery
appears indicated in the following situations:
(1) Computerized testing may provide an objective screening for
cognitive problems in case of self-reported cognitive deﬁcits.
However, subjective complaints always call for a concomitant
screening for depressed mood, because of the robust ﬁnding
that subjective cognitive complaints often reﬂect mood rather
than objective performance.5,6 When objective cognitive
problems become evident and more detailed information is
required a subsequent more comprehensive standard neuro-
psychological assessment may be indicated.
(2) Because of the high objectivity and time-efﬁcient method of
administration, computerized tests seem to be an ideal
approach if frequent repeated testing is required, for instance
to monitor the effect of medical interventions or of acute
changes in the course of the disease.
(3) In conjunction with co-registered EEG-data, computer tests can
be used to assess the impact of interictal discharges on
cognition and vice versa.
(4) Postictal computerized testing may provide information on
negative symptoms and the dynamics of seizure-related
cognitive dysfunctions. The differential postictal recovery of
material-speciﬁc memory functions in temporal lobe epilepsies
has been shown to be related to the lateralization of the seizure
onset.7
(5) The use of computerized naming (frontal and temporal
functions) and line-bisection tests (parietal functions) during
invasive EEG-monitoring or awake surgery can facilitate the
surgeon’s decision to excise or spare particular areas of the
brain.
(6) Computerized tests are ideal for experimental assessments in
cognitive neuroscience. Experiments performed on a group
level under controlled conditions, however, may not be
suitable for routine diagnostics and for individual level analysis
since they lack standardization with normative data.
(7) To date there are no standardized computer tests which have
been used in patients with epilepsy outside the clinic or
outpatient setting. However, a ﬁrst attempt of assessing
cognitive and behavioral effects of antiepileptic pharmaco-
therapy8 demonstrated the potential of computerized tests to
assess patients outside institutional settings in speciﬁc
situations, at speciﬁc locations or times.
For all suggested indications it is essential that the chosen
measures are valid in regard to the diagnostic target.9
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computerized testing
Almost all of the cognitive domains examined by traditional
neuropsychological tests can also be assessed by computerized
testing procedures. The cognitive domains which are best examined
using computer-based methods are those where computers have
advantages over routine paper-pencil or face-to-face examinations.
In the ﬁrst line these are all functions for which time or precision are
critical, both in terms of stimulus presentation and the required
reaction/behavior. This concerns the domains of attention and
decision making (reaction or decision times), perception (signal
detection, threshold measurements, visual ﬁeld assessment),
hemispheric language or motor dominance (dichotic listening,
tachistoscopy, ﬁnger tapping), visuo-spatial orientation and navi-
gation (visual scanning, neglect tests, mazes, virtual reality),
working memory as well as span and supraspan tasks (n-back
tasks, Corsi block tapping), learning and memory (pools of stimuli for
retrieval of items following random selection or a given algorithm;
object location tasks), language functions (response times along
with word ﬁnding difﬁculties and/or naming problems), and social
cognition (Theory of Mind).
However, while this list gives an idea about possible applica-
tions of computer tests, it is not meant to imply that there is
sufﬁcient published evidence about tasks which can be selected for
valid routine computerized diagnostics at present. Often comput-
erized tasks are used to address only a single scientiﬁc question
(see surface or intracranial cognitive event-related potentials
in epilepsy), in some cases the validity and reliability of the
tasks per se are in question (see value of dichotic listening or
tachistoscopy for functional brain organization), or the tasks are
in an experimental stage of development or have not yet been
evaluated in epilepsy (see psycho-physics).
5. Overview of available computer tests
Given the potential advantages of computerized testing it is
surprising how little use of such tests has, so far, been made in theTable 1
Overview of the cognitive domains which are assessed by the different computerized 
CALCAP CANTAB CCTE CD
Attention
Alertness U U – U 
Selective attention U U U U 
Sustained attention U U – U 
Divided attention – – – – 
Interference/Flexibility U U – – 
Vigilance – U– – U 
Working memory
Verbal U – U U 
Nonverbal – U – U 
Verbal memory
Immediate – U U U 
Delayed – U – U 
Nonverbal memory
Immediate – U U U 
Delayed – U U U 
Language
Fluency – – – – 
Naming – U – – 
Lexical discrimination U – – – 
Other functions
Finger tapping – – – U 
Visual/spatial functions U U U U 
Incidental memory – – U – ﬁeld of epilepsy, and that it has not become an integral part of
standard or routine diagnostics.10,11
The following section comprises brief descriptions of computer
tests available which have been applied as main cognitive measure
in published studies in the ﬁelds of epilepsy or antiepileptic
drug research. The computerized batteries have primarily been
identiﬁed via literature search in PubMed x(http://www.ncbi.nlm.
nih.gov/pubmed/?term=(epilep*[title]+cognit*+computer*)+OR+
(antiepileptic+drug*+cognit*+computer*)). In addition, surveys of
neuropsychological praxis in epilepsy were screened for citations
of computerized tests.10–12 Experimental cognitive paradigms (e.g.
those used exclusively in functional imaging experiments) were
not considered, because of the lack of clinical utility due to missing
or insufﬁcient normative data. A related and rather complementa-
ry review by Wild et al.13 provides an overview of 18 computerized
assessment tools in the ﬁeld of dementia. With just two tests
(CANTAB, CNTB) the overlap of this former and our present review
is minimal.
The questions which have been addressed by computerized
neuropsychological tests in the ﬁeld of epilepsy-related to
screening for deﬁcits (i.e. whether cognitive impairments are
evident or not, or to objectify subjective complaints),14 to assess
the cognitive effects of antiepileptic drugs in patients or healthy
subjects,15 to evaluate interictal or postictal cognitive
change,7,16,17 or the effects of acute interventions (e.g. vagal
nerve stimulation,18 interruption of nonconvulsive status
epilepticus 19,20).
Table 1 provides a comparative overview of cognitive functions
which authors have claimed to assess by use of the respective
computer test. Table 2 summarizes and compares the require-
ments, features and test criteria of these tests.
5.1. California Computerized Assessment Package (CALCAP1)
The 7 subtests of the CALCAP (http://www.calcaprt.com) assess
simple and choice reaction times, visual selective attention,
response reversal and rapid visual scanning, form discrimination
and working memory (1-back and 2-back tasks). Thus the batterybatteries.
R CNT CNTB FePsy NeuroCog FX TAP
– U U U U
– U U U U
U – U – U
U – – – U
– – - U U
– – U – U
– – U U U
U – U – –
– U U U –
U U – U –
– U U U –
– U – U –
– – - U –
– U U – –
– – – – –
– U U – –
– U U – U
– – U – –
Table 2
Requirements, features and test criteria of the different computerized batteries.
CALCAP CANTAB CCTE CDR CNT CNTB FePsy NeuroCog FX TAP
Price 385s Variable 1250s n.a. Supplied
as service
n.a. ? 1980s Licensed to Eisai 1190s (once,
no usage imitation)
System requirements Windows, DOS
80286+CPU 512K
RAM 2MB HD
Windows, touchscreen Windows,
soundcard,
touchscreen
Most Windows
PCs & available
over internet
PC ? PC PC/Laptop, Windows,
soundcard
Windows, soundcard,
2 USB-Ports
Language support EN, ESP, FL FRA,
NOR, DEN
Interface: EN; feedback:
several languages
GER >65 Languages EN ? 21, incl. EN, FRA,
GER, ESP, ITA
GER AR*, CHIN, DEN, EN,
ESP, FIN, FRA, GER, ITA,
LIT, NED, POR
Number of subtests
(and variations)
7 Up to 25 8 12 2 11 11 (24) 8 13 (31)
Administration time <25min 30min 18min 30–45min 50min 120min <30min Subtest durations
from 2 to 30min
Normative data (N) >1000 250–1450 83 >8000 500 ? 250 244 94–811
Age range (years) 17–90 4–80+ 20–60 5–87 6–90 ? 7–80 17–80 6–90, variable
Control for education U U – Not for clinical
trial applications
U ? – – U
Test–retest norms U (N=175) – U (N=46) U U U – U (N=44) –
RCIs – – U – – U – U –
Retest-reliablities (r) 0.20–0.68 0.09–0.86 0.40–0.79 0.40–0.90 0.80 ? 0.70–0.90 (patients) 0.21–0.69
(healthy controls)
0.70 –0.85 (patients)
0.34 –0.96
Parallel versions – 0–15 1 >50 U ? Some tests 6 predeﬁned or
random material
Some subtests
Devised for epilepsy – – U – – – U U –
Validated in epilepsy – U U – – – U U –
Epilepsy-speciﬁc sensitivity
Localization/lateralization – – U – – – – U –
IEDs and/or seizures – – – – – – U – -
AED treatment U – U U U U U U –
Special features Auditory
instructions
U
EEG coregistration – – – U U – U – –
Summary score – – – – U U U –
Graphical cognitive proﬁle U – U – U ? U U
n.a., Not available; ?, no information available; HD, hard disk; HC, healthy controls; pat., patients; AED, antiepileptic drug.
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analysis in healthy volunteers revealed two primary factors
reﬂecting 1. ‘‘Simple reaction time’’ and 2. ‘‘Decision speed’’.21
These two factors were distinct from those derived from traditional
paper-pencil-tests. The ﬁrst comprised the simple reaction time
test and the second all other subtests. The battery is designed for
longitudinal studies providing normative data for up to six
repeated examinations. Practice sessions before each subtest
ensure an understanding of the task instructions and minimize
practice effects in repeated assessments. An abbreviated version
based on four subtests assessing speed of processing and working
memory is available and takes 8–10 min to complete.
Application in epilepsy: The CALCAP has not been validated in
patients with epilepsy, but was applied in a prospective antiepi-
leptic drug withdrawal study in patients with epilepsy demon-
strating an increase of completely unimpaired patients from 11% at
baseline to 28% at follow-up.15
5.2. Cambridge Neuropsychological Test Automated Battery (CANTAB)
The CANTAB (http://www.cantab.com) consists of a selection
of 25 tests that assess a wide range of cognitive domains,
including executive function, attention and memory. All tests
are supposed to be culturally independent and most are non-
linguistic. Factor analysis revealed four factors reﬂecting (1)
general learning and memory ability, (2.)speed of responding,
(3) executive processes, and (4) visual perceptual ability.
CANTAB tests have been validated22–24 in over one thousand
peer reviewed articles attesting to the sensitivity of these tests
in a number of disease areas. The validation study in epilepsy
evaluated a heterogeneous group of 15 patients with epilepsy25
and compared three subtests of the CANTAB [memory (Delayed
matching to sample (DMS), Paired Associate Learning (PL)) and
executive functions (Stockings of Cambridge (SOC)] with tradi-
tional paper-pencil tests [including Wechsler Memory Scale
revised (WMS-R), the Category Test, the Trail Making Test
(TMT) and the Wechsler Adult Intelligence Scale (WAIS-III)].
When classifying the patients as impaired (z-score 2 on two
or 1.5 on three of ten tests) vs. unimpaired, the concordance
between these two different approaches was 80%. Performance
in DMS was correlated with the results of the Visual Paired
Associates subtest of the WMS-R. Scores obtained in the PL were
related to several test parameters including verbal IQ, TMT-B as
well as verbal and visual memory indices. Executive perfor-
mance assessed via SOC also correlated with several measures
including memory indices and intelligence, but not with the
TMT-B – a test of executive function.
Application in epilepsy: Apart from the above-mentioned small
validation study, the sensitivity of the CANTAB to different types or
etiologies of epilepsy, antiepileptic drugs, seizures or interictal
epileptiform activity has not yet been demonstrated.
5.3. Computerized Cognitive Testing in Epilepsy (CCTE)
The CCTE is a reliable neuropsychological screening instrument
that comprises the following eight tasks: digit span forward and
backward, focused attention and visual scanning, visuospatial
memory, incidental memory, verbal learning and ﬁgural memo-
ry.26,27 The self-administrable test battery utilizes a touchscreen
and it takes about 30 min to complete; the results can be displayed
graphically immediately after examination in comparison to age-
related normative data. Two parallel versions and RCIs allow for
repetitive assessment of a patient’s cognitive proﬁle. A factor
analysis in a mixed sample of 240 patients with epilepsy and 83
healthy volunteers revealed two factors reﬂecting (1) attention and
(2) memory.27 Up to now the CCTE is only available in Germanlanguage, but the development of multilingual versions is in
progress.
Application in epilepsy: The authors have demonstrated
sensitivity to medical treatment (untreated < monotherapy
< polytherapy) and worse verbal memory performance in patients
with left versus right mesial temporal lobe epilepsy.27 Moreover,
performance in subtests of the CCTE correlates with results in
corresponding paper-pencil tests which have proven validity in the
ﬁeld of epilepsy.27
5.4. Cognitive Drug Research (CDR) computerized assessment system
The CDR Computerized Assessment System (http://
www.bracketglobal.com/services/cognition) is a sensitive and
validated computerized cognitive assessment system speciﬁcally
designed for clinical trials.28 The CDR System assesses the core
aspects of cognitive function (psychomotor speed, attention,
working memory, episodic verbal and nonverbal memory), which
underpin the ability to conduct the activities of daily living. Factor
analyses in healthy volunteers and in a population with dementia
revealed four to ﬁve underlying factors reﬂecting speed and quality
of attention and memory processes.29–31 Besides the core battery
additional tests (e.g. motor control, executive functions, psycho-
physical ﬂicker fusion thresholds) and automated questionnaires
are available. Furthermore it allows for EEG coregistration to
obtain evoked potentials for detected and non-detected targets as
well as correct and incorrect decisions or recognitions. The CDR
System was developed during the late 1970s and early 1980s to
provide clinical trials with a tool which could reliably measure
change over time in cognitive function associated with the use of
novel treatments and/or disease progression. Since 1984 it has
been employed in almost 1400 clinical trials worldwide. It has
been used extensively in all phases of drug development in over
60 clinical conditions. The core-assessments are brief to complete
(18 min) and have numerous parallel forms (>50) and language
versions (>65). The CDR System is simple to administer, allowing
non-specialists to be rapidly trained in its use. The CDR System has
the largest database ever assembled of cognitive data from clinical
trials.
Application in epilepsy: The CDR System was applied in a single
study on the cognitive and psychomotor effects of remacemide and
carbamazepine in newly diagnosed epilepsy,32 but has not yet
been explicitly validated in patients with epilepsy.
5.5. Cognitive Neurophysiological Test (CNT)
The CNT uniquely combines cognitive task performance mea-
sures with simultaneous recording of EEG and evoked potential
measures to form a single index of how a drug or illness affects
overall neurocognitive function. The advantage of the CNT is that it
takes into account not only the speed and accuracy of cognitive task
performance but also the amount and type of neural resources and
effort required to produce that level of performance, as well as the
level of alertness. The practical consequence of this additional
knowledge is increased sensitivity and speciﬁcity to the effects of a
drug.33,34 The CNT is an automated hardware and software system
with a fast application EEG hat that allows test administration by
personnel with minimal training.35,36 The primary cognitive
functions measured are working memory (n-back task) and
sustained attention,37 with options for verbal episodic memory
(word recognition task) and divided attention. In addition to an
overall index, sub-indices are provided for each cognitive task, EEG
and alertness. The CNT is not commercially available.
Application in epilepsy: Apart from its use in studies on the
cognitive effects of antiepileptic drugs in healthy subjects,38–41 the
test has not yet been validated in patients with epilepsy.
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The CNTB is primarily based on traditional neuropsychological
tests that were adapted for computer-aided presentation and
registration.42,43 Thus the CNTB is not self-administrable and oral
stimuli (verbal memory test) still have to be read aloud by the
investigator. In approximately 50 min the 11 subtests of the CNTB
assess motor speed (ﬁnger tapping), information processing (simple
and choice reaction times), attention, verbal and spatial memory
(word list learning and recall, paired associate learning, visual
memory, visual matching delayed recall), language (confrontation
naming), as well as spatial abilities (visual matching).13 In addition
to subtest results a summary score reﬂecting the global performance
across all subtests is provided. The CNTB has two alternative forms.
However, the battery was originally devised for dementia and used
as outcome measure in clinical trials in this domain.
Application in epilepsy: To our knowledge, the battery has not
yet been applied or validated in patients with epilepsy. The test has
been used, however, in a study on the cognitive effects of the
antiepileptic drug topiramate in healthy subjects.44 For their
purpose the authors of that study calculated RCIs for the summary
score based on the performance of 38 healthy subjects before and
6, 12 and 24 weeks after receiving placebo.44
5.7. FePsy ‘The Iron Psyche’
The FePsy (http://www.fepsy.com) comprises a battery of 11
computerized tests (24 when considering all subtest variations;
auditory reaction time, visual reaction time, binary choice reaction
time, tapping task, computerized visual searching task, verbal and
visual recognition tasks, vigilance task, seashore rhythm task, card
sorting task, visual half ﬁeld tasks, Corsi block tapping, naming test,
as well as a memory and a cognitive complaints questionnaire) for
cognitive neuropsychological functions and is built around a
powerful relational database system which stores all results. These
results can easily be converted into statistical or other database
programs. FePsy includes a subset of tests for the measurement of
side effects of drugs45 (Epilepsy, Cancer, HIV) and is also used in
other ﬁelds (Parkinson, Schizophrenia, Diabetes), covering arousal,
short-term memory, mental speed, vigilance, naming as well as
some questionnaires. A factor analysis in 747 patients with
epilepsy revealed six factors reﬂecting (1) working memory/
memory/attention, (2) simple reaction time, (3) motor perfor-
mance, (4) problem solving, (5) choice reaction time, (6)
impulsivity. It runs on every modern PC. Use of a touchscreen is
an option. FePsy is available in almost all European languages, 21 in
total. FePsy easily connects to the EEG to analyze simultaneous EEG
signals and psychological performance. Test-retest norms (e.g.
RCIs) are not yet provided.
Application in epilepsy: Several multi-center drug trials demon-
strated the usefulness of the FePsy for the assessment of drug-
related cognitive effects.45–47 Simultaneous EEG recording and
cognitive testing have proven to be a useful procedure to assess the
cognitive effects of frequent, short, difﬁcult-to-detect seizures
(subtle nonconvulsive epileptic seizures) and of epileptiform EEG
discharges in the absence of seizures.48–50
5.8. NeuroCog FX
The NeuroCog FXW51 is a reliable and valid computerized
neuropsychological battery for the repeated assessment of patients
with epilepsy and other neurological diseases. In less than 30 min
eight subtests assess attention (simple reaction, go/no-go, inverted
go/no-go), short-term-memory (digit span), working memory (2-
back task), verbal and ﬁgural memory (learning and recognition),
and language (phonemic ﬂuency).Explorative principal component analysis on raw scores from
the total sample of subjects (healthy subjects and patients N = 379)
extracted two factors (Eigenvalue > 1, VARIMAX rotation) which
could best be described as ‘‘processing or operations’’ on the one
hand (digit span, 2-back, verbal and ﬁgural memory, and phonemic
ﬂuency), and ‘‘psychomotor speed’’ on the other hand (reaction
time-based tests: simple reaction, go/no-go, and inverted go/no-
go). The model explained 60% of the variance. Based on this
analysis, two scores of overall performance are calculated in
addition to results on individual subtests and a total score. The two
summary scores share about 16% of common variance (r = 0.42,
p < 0.001). Random stimulus selection and RCIs allow for
longitudinal assessments and determination of statistically
signiﬁcant change in individual patients. Special features include
a graphical display of the standardized cognitive proﬁle for proﬁle
analysis and export of data for data collection in a data base.
NeuroCog FX has its origins in epilepsy, but the test in its
present form had been constructed for use in CNS diseases in
general. It has been applied in monitoring in neuro-oncology and
neurosurgery.52,53Moreover, the test has been used in neurological
studies on patients with spinocerebellar ataxia54 and myotonic
dystrophy.55 Major limitations are that, at present, the test is only
available in German and that the patient’s reactions have to occur
within a ﬁxed time limit so that patients with more severe
psychomotor slowing cannot be tested with this tool.
The NeuroCog FX has recently been licensed for exclusive
distribution and use by Eisai.
Application in epilepsy: Concurrent validity of the NeuroCog FX
with a battery of standard neuropsychological tests was estab-
lished in healthy subjects and, separately, in patients with
epilepsy.56 An unpublished bachelor thesis57 demonstrated
sensitivity of the test to several clinical parameters including
age at seizure-onset, focus localization (frontal vs. temporal), and
pharmacological treatment effects (drug load and speciﬁc antiepi-
leptic drugs) in a cohort of 290 patients with epilepsy. This work
furthermore conﬁrmed the two-factor structure of the test.
5.9. Test of attentional performance
The TAP (German: Testbatterie zur Aufmerksamkeitspru¨-
fung) (http://www.psytest.net) is a collection of computerized
tests for the assessment of attentional functions and visual
processing among children and adults. It consists of 13 different
subtests (31 when considering all subtest variations) covering
different aspects of attention such as alertness, selective attention,
divided attention, covered shift of attention, ﬂexibility, working
memory, sustained attention and vigilance. Furthermore several
subtests for the assessment of visual ﬁeld and neglect are included.
Each subtest is preceded by a pretest to practice the exercise before
starting the main test. The test is available in 13 different
languages. Normative data exists for most of the subtests for adults
and for about half of the subtests for children. The norm-values are
calculated automatically under consideration of age, sex and
educational level of the subject. The TAP has proven to be a reliable
instrument in the context of clinical examination, educational
psychology, assessment of ﬁtness to drive and scientiﬁc research.
It has been used in a variety of different research projects,
numerous articles have been published during the more than 20
years since the ﬁrst release of the TAP. Despite the fact that the
TAP was devised to assess various aspects of attention, factor
analysis indicates that the great number of subtests mainly
reﬂect two constructs: (1) ‘‘alertness’’ and (2)‘‘selective, i.e.
divided attention’’. 58
Application in epilepsy: In a survey on neuropsychological
practice in German-speaking epilepsy centers the TAP was the
most frequently used computerized test.11,12 However, only up to
J.-A. Witt et al. / Seizure 22 (2013) 416–423422ﬁve of the 13 TAP subtests (i.e. alertness, divided attention, go/no-
go, reaction change and working memory) were used complemen-
tary to a comprehensive paper-pencil test battery. This under-
scores that the TAP, as a test battery primarily focusing on
attention, was not devised as a stand-alone computer test, but rather
complements other neuropsychological diagnostic procedures. The
test has been used for assessment of attention and executive
functions in patients with benign partial childhood epilepsy,37
juvenile myoclonus epilepsy,34 or for the determination of the
cognitive status after surgery.26Parts of it have also been used for the
assessment of cognitive effects of antiepileptic drugs.59
6. Summary
In contrast to the plethora of coexistent neuropsychological
paper-pencil tests which are routinely applied in the ﬁeld of
epilepsy,10,11 only a relatively small number of computer tests
has been used in patients with epilepsy or in antiepileptic drug
trials. Among the nine computer tests reviewed here, merely three
(33%), namely the CCTE, the FePsy and the Neurocog FX were
devised for epilepsy. Consequently these three tests have been
validated in patients with epilepsy. The CCTE and the Neurocog FX
demonstrated concurrent validity with established paper-pencil
tests with proven validity in epilepsy.14,27 Moreover, the CCTE has
shown differential results depending on the lateralization in
mesial temporal lobe epilepsy, the Neurocog FX is sensitive to
several clinical parameters like age at seizure-onset or focus
localization (frontal vs. temporal) and the FePsy can disclose the
impact of acute epileptic EEG discharges on cognitive functioning.
Some degree of sensitivity to antiepileptic pharmacotherapy
(mostly to the total drug load) was demonstrated for most of
the reviewed computer batteries (CALCAP, CCTE, CDR, CNT, CNTB,
FePsy, and Neurocog FX). However, information on the clinical
validity of the tests in epilepsy is mostly limited to single studies
and conclusions about differential effects are derived from group
statistics. Consequently the reported sensitivities do not imply that
the respective computer tests will reliably discriminate between
individual patients on the basis of the listed clinical parameters
(e.g. side or site of the seizure-focus). The same is true for the
sensitivity of the tests to antiepileptic drugs. Thus one cannot
presently conclude that any of the tests is appropriate for the
individual monitoring of antiepileptic pharmacotherapy 2. More
information on the sensitivity and speciﬁcity of the measures in
relation to an external criterion would be highly appreciated (e.g.
receiver-operator characteristics).
Nevertheless, the CCTE, the FePsy and the NeurocogFX appear
suitable for screening purposes in the ﬁeld of epilepsy, although
they are not interchangeable since they assess somewhat different
cognitive functions (cf. Table 1). Among these three tests delayed
verbal (recognition) memory for instance is only assessed within
the NeurocogFX. Although the test batteries are designed and
proposed to evaluate several cognitive (sub)functions, the
independence of the various test parameters is questionable,
because corresponding factor analyses revealed comparably few
underlying basic concepts.
Test-retest norms and parallel versions are necessary for
repeated testing. Both, the CCTE and the Neurocog FX fulﬁll this
criterion and provide reliable change indices. The special advan-
tage of the FePsy is that it allows the coregistration of the EEG in
order to detect the impact of epileptiform discharges or non-
convulsive seizures on cognition.
7. Outlook
The steadily increasing availability of computer devices and
internet access will surely change the current landscape ofcomputerized testing. Web-based assessments could transfer
cognitive assessments to the patients’ homes. This could be
especially helpful in longitudinal long-term follow up. Futhermore,
web-based data collection allows for a de-centralized application
of tests in multicenter studies and evaluations of large cohorts of
patients. The potential of mobile testing platforms (for instance
cell phones or other portable devices like multimedia tablets)
may lead to interesting new applications of neuropsychological
testing. For example, Frings et al.8 already demonstrated the
beneﬁts of handheld computers with regard to the early detection
of cognitive and behavioral side effects of antiepileptic therapy
with levetiracetam.
How and which computerized tests can be incorporated in
standard neuropsychological assessment remains a matter of
choice. It is important that tests are used that have been validated
and standardized. There is a long-standing history of publications
accumulating evidence for the usefulness of paper-pencil tests in
epilepsy-related diagnostic areas. To date, there is much less
published evidence supporting the usefulness of computerized tests
in patients with epilepsy. In particular, there is a lack of studies
comparing standard paper-pencil and computerized tests addres-
sing the same cognitive domains. With this in mind, a selection of
tests for the domains of interest can be made on basis of Table 1.
For the time being, it is important to emphasize that, in most
diagnostic situations, exclusive computerized testing in epilepsy
cannot yet substitute a thorough neuropsychological examination
of patients with epilepsy, especially not in surgical settings.
Irrespective of the testing procedure, validity (clinical and
ecological) must be the major selection criterion for neuropsycho-
logical instruments. Thus, published evidence is essential to prove
the suitability of tests with regard to speciﬁc diagnostic questions.
Only this will ensure an evidence-based future for neuropsycho-
logical testing.
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